GlaxoSmithKline 178 Taxation information for shareholders Information for shareholders Stamp duty UK stamp duty or stamp duty reserve tax SDRT will, subject to A summary of the main tax consequences for holders of shares certain exemptions, be payable on the purchase of shares at a and ADRs who are citizens or residents of the UK or the USA is rate of 0.5 per cent of the purchase price.
There is a minimum set out below.
It is not a complete analysis of all the possible tax charge of 5 where a stamp duty liability arises.
consequences of purchase or ownership of these securities.
It is intended only as a general guide.
Holders are advised to consult US shareholders their advisers with respect to the tax consequences of the purchase and ownership of their shares or ADRs, and the The following is a summary of certain UK taxation and USA consequences under state and local tax laws in the USA and federal income tax considerations that may be relevant to a the implications of the new UK US Income Tax convention.
US holder of shares or ADRs.
This summary only applies to a shareholder that holds shares or ADRs as capital assets, is a This statement is based upon UK and US tax laws and practices citizen or resident of the USA or a domestic corporation or that at the date of this report.
is otherwise subject to United States federal income taxation on The new UK US Income Tax Convention came into force on a net income basis in respect of the shares or ADRs, and is not 31st March 2003.
The provisions of the new treaty apply for UK resident in the UK for UK tax purposes and does not hold shares tax purposes from 1st April 2003 UK Corporation Tax, 6th April for the purposes of a trade, profession or vocation that is carried 2003 UK Income Tax and Capital Gains Tax and 1st May 2003 on in the UK through a branch or agency.
For US tax purposes, the provisions of the new treaty apply from 1st May 2003 Withholding Taxes and Taxation of dividends 1st January 2004 all other US taxes.
However, holders of shares The gross amount of dividends received including amounts in or ADRs have the ability to elect to continue to use the respect of associated tax credit and UK withholding tax is treated provisions of the previous treaty for 12 months following the as foreign source dividend income for US tax purposes.
It is not new treatys entry into force.
An election must be made in eligible for the dividend received deduction allowed to US advance of the first event to which the new treaty would apply.
Dividends on ADRs are payable in US dollars: dividends on shares are payable in Sterling.
Dividends paid in US holders of ADRs generally will be treated as the owners of pounds Sterling will be included in income in the US dollar the underlying shares for the purposes of the current USA UK amount calculated by reference to the exchange rate on the day double taxation conventions relating to income and gains the dividends are received by the holder.
Subject to certain Income Tax Convention, estate and gift taxes Estate and Gift exceptions, an individual eligible US holder will be subject to US Tax Convention and for the purposes of the US Internal Revenue taxation at a maximum rate of 15 per cent in respect of qualified Code of 1986, as amended the Code.
Shareholders are advised to The following analysis deals with dividends paid after 6th April consult their own Tax Advisers to confirm their eligibility.
1999 when Advance Corporation Tax ACT was abolished.
Taxation of capital gains UK shareholders Generally, US holders will not be subject to UK capital gains tax, but will be subject to US tax on capital gains realised on the sale Taxation of dividends or other disposal of shares or ADRs.
From 6th April 1999, the rate of tax credits was reduced to one ninth.
As a result of compensating reductions in the rate of tax Estate and gift taxes on dividend income, there is no increase in the tax borne by UK Under the Estate and Gift Tax Convention, a US shareholder resident individual shareholders.
Tax credits are, however, no is not generally subject to UK inheritance tax.
longer repayable to shareholders with a tax liability of less than the associated tax credit.
Stamp duty UK stamp duty or SDRT will, subject to certain exemptions, be Taxation of capital gains payable on any issue or transfer of shares to the ADR custodian UK shareholders may be liable for UK tax on gains on the or depository at a rate of 1.5 per cent of their price if issued, disposal of shares or ADRs.
They may also be entitled to the amount of any consideration provided if transferred on indexation relief and taper relief on such sales.
Indexation relief sale, or their value if transferred for no consideration.
is calculated on the market value of shares at 31st March 1982 and on the cost of any subsequent purchases from the date of No SDRT would be payable on the transfer of an ADR.
Indexation relief for individual shareholders stamp duty should be payable on the transfer of an ADR ceased on 5th April 1998.
Taper relief is available to individual provided that the instrument of transfer is executed and remains shareholders who hold or are deemed to hold shares for at least at all times outside the UK.
Any stamp duty on the transfer of three years before they are sold.
an ADR would be payable at a rate of 0.5 per cent of the consideration for the transfer.
Any sale of the underlying shares Inheritance tax would result in liability to UK stamp duty or, as the case may be, Individual shareholders may be liable to inheritance tax on the SDRT at a rate of 0.5 per cent.
There is a minimum charge of transfer of shares or ADRs.
Tax may be charged on the amount 5 where a stamp duty liability arises.
by which the value of the shareholder's estate is reduced as a result of any transfer by way of gift or other disposal at less than full market value.
Such a gift or other disposal is subject to both UK inheritance tax and US estate or gift tax.
The Estate and Gift Tax Convention would generally provide for tax paid in the USA to be credited against tax payable in the UK.
179 GlaxoSmithKline Cross reference to Form 20-F This table has been provided as a cross reference from the information included in this Annual Report to the requirements of Form 20-F.
Item Page Item Page 8 Financial information 1 Identity of directors, senior management and advisors n a A Consolidated statements and other financial information 2 Offer statistics and expected timetable n a Financial statements See Item 18 3 Key information Legal proceedings 116-122 A Selected financial data 160-162,174 B Significant changes D Risk factors 76-78 Note 31 Post Balance Sheet Event 122 4 Information on the company 9 The offer and listing A History and development of the company Inside front cover A Share price history 176 B Business overview C Markets 176 Products 25-26,28 10 Additional information Competition 27-28 B Memorandum and Articles of Association Footnote i Regulation 29-30 C Material contracts n a Marketing and distribution 18,23 D Exchange controls 177 Manufacture and supply 24 E Taxation 178 Research and development 07-17 H Documents on display 177 Intellectual property 30-31 11 Quantitative and qualitative disclosures about market risk Environment, health and safety 31-32 Treasury policies 74-75 Access to medicines 19 Note 34 - Financial instruments and related disclosures 125-128 Investment in communities 21-22 C Organisational structure 150-152 12 Description of securities other than equity securities n a D Property, plants and equipment 71 13 Defaults, dividend arrearages and delinquencies n a Environmental responsibility 71 14 Material modifications to the rights of security holders Note 6 Segment information 100-102 and use of proceeds n a Note 17 Tangible fixed assets 109 15 Controls and procedures 39-42 5 Operating and financial review and prospects A Operating results 16 [Reserved] 2004 and 2003 61-78 A Audit Committee financial expert 40 2003 and 2002 79-86 B Code of ethics 41 B Liquidity and capital resources 71-75 C Principal accountant fees and services 104 C Research and development, patents and licenses, etc.
07-17,60 D Exemptions from the listing standard for audit committees n a D Trend information 60 E Purchases of equity securities by the issuer and affiliated E Balance sheet arrangements n a purchasers 114 F Tabular disclosure of contractual obligations 72 17 Financial statements n a 6 Directors, senior management and employees 18 Financial statements A Directors and senior management 34-35 Independent auditors report Footnote ii B Compensation Consolidated statement of profit and loss 90-91 Remuneration Report 43-58 Consolidated statement of total recognised gains and C Board practices losses 90-91 Corporate governance 36-42 Consolidated statement of cash flow 92-93 D Employees Consolidated balance sheet 94 GlaxoSmithKline people 20 Reconciliation of movements in consolidated equity Note 35 Employee costs 129-135 shareholders funds 94 Financial record 162 Company balance sheet 95 E Share ownership Notes to the financial statements 96-152 GlaxoSmithKline people 20 19 Exhibits Footnote ii Note 36 Employee share schemes 136-138 Share options 54-55 Footnote Incentive plans 55-56 i Information responsive to this item is incorporated by reference Directors interests 53,58 to Memorandum and Articles of Association of GlaxoSmithKline 7 Major shareholders and related party transactions at pages 3536 of the Groups Annual Report on Form 20-F for the year ended 31st December 2000.
A Major shareholders 177 B Related party transactions ii See the companys Form 20-F filing with the Securities and Exchange Note 32 Related party transactions 122 Commission.
